These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 14695425)

  • 1. Gentamicin and CFTR.
    Kida Y
    N Engl J Med; 2003 Dec; 349(26):2570. PubMed ID: 14695425
    [No Abstract]   [Full Text] [Related]  

  • 2. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
    Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E
    N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
    Kerem E
    Curr Opin Pulm Med; 2004 Nov; 10(6):547-52. PubMed ID: 15510065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
    Lukacs GL; Durie PR
    N Engl J Med; 2003 Oct; 349(15):1401-4. PubMed ID: 14534332
    [No Abstract]   [Full Text] [Related]  

  • 5. Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis.
    Hamilton JW
    Lancet; 2001 Dec; 358(9298):2014-6. PubMed ID: 11755605
    [No Abstract]   [Full Text] [Related]  

  • 6. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations.
    Wilschanski M; Famini C; Blau H; Rivlin J; Augarten A; Avital A; Kerem B; Kerem E
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):860-5. PubMed ID: 10712334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
    Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
    J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.
    Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.
    Rubenstein RC; Egan ME; Zeitlin PL
    J Clin Invest; 1997 Nov; 100(10):2457-65. PubMed ID: 9366560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basic protocol for transepithelial nasal potential difference measurements.
    Schüler D; Sermet-Gaudelus I; Wilschanski M; Ballmann M; Dechaux M; Edelman A; Hug M; Leal T; Lebacq J; Lebecque P; Lenoir G; Stanke F; Wallemacq P; Tümmler B; Knowles MR
    J Cyst Fibros; 2004 Aug; 3 Suppl 2():151-5. PubMed ID: 15463949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Might Brushed Nasal Cells Be a Surrogate for CFTR Modulator Clinical Response?
    Pranke I; Hatton A; Masson A; Flament T; Le Bourgeois M; Chedevergne F; Bailly C; Urbach V; Hinzpeter A; Edelman A; Sermet-Gaudelus I
    Am J Respir Crit Care Med; 2019 Jan; 199(1):123-126. PubMed ID: 30326728
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term azithromycin in cystic fibrosis: another possible mechanism of action?
    Pradal U; Delmarco A; Morganti M; Cipolli M; Mini E; Cazzola G
    J Chemother; 2005 Aug; 17(4):393-400. PubMed ID: 16167518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal potential difference measurements to assess CFTR ion channel activity.
    Rowe SM; Clancy JP; Wilschanski M
    Methods Mol Biol; 2011; 741():69-86. PubMed ID: 21594779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CFTR-mediated protein secretion defect: pharmacological correction.
    McPherson MA; Pereira MM; Russell D; McNeilly CM; Morris RM; Stratford FL; Dormer RL
    Pflugers Arch; 2001; 443 Suppl 1():S121-6. PubMed ID: 11845317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis.
    Clancy JP; Bebök Z; Ruiz F; King C; Jones J; Walker L; Greer H; Hong J; Wing L; Macaluso M; Lyrene R; Sorscher EJ; Bedwell DM
    Am J Respir Crit Care Med; 2001 Jun; 163(7):1683-92. PubMed ID: 11401894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects.
    Egan ME; Pearson M; Weiner SA; Rajendran V; Rubin D; Glöckner-Pagel J; Canny S; Du K; Lukacs GL; Caplan MJ
    Science; 2004 Apr; 304(5670):600-2. PubMed ID: 15105504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation specific therapy in CF.
    Kerem E
    Paediatr Respir Rev; 2006; 7 Suppl 1():S166-9. PubMed ID: 16798551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combating cystic fibrosis: in search for CF transmembrane conductance regulator (CFTR) modulators.
    Noy E; Senderowitz H
    ChemMedChem; 2011 Feb; 6(2):243-51. PubMed ID: 21275046
    [No Abstract]   [Full Text] [Related]  

  • 19. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis.
    Lubamba B; Lecourt H; Lebacq J; Lebecque P; De Jonge H; Wallemacq P; Leal T
    Am J Respir Crit Care Med; 2008 Mar; 177(5):506-15. PubMed ID: 18006891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model.
    Du M; Keeling KM; Fan L; Liu X; Bedwell DM
    J Biol Chem; 2009 Mar; 284(11):6885-92. PubMed ID: 19136563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.